As of November 6, 2026, NLS Pharmaceutics Ltd. is a publicly traded company (Nasdaq: NCEL). The largest holder reporting an active stake on Schedule 13D is League Jinn Sarl, at 25.3%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Founder or officer holdings: Michel Revel, the executive officer and a director (20.2%); Ronen Twito, the executive officer and a director (6%) (Schedule 13D, May 4, 2026).
Is this your company?
About to sign with, pay or invest in NLS Pharmaceutics Ltd.? See the free Snapshot first.
Free to see. No signup.
Is NLS Pharmaceutics Ltd. a real, registered company?
- NewcelX Ltd. files with the SEC under CIK 1783036 (its SEC filings).
- Its shares are listed under the ticker NCEL on Nasdaq (SEC company record).
- Incorporated in V8, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under NewcelX Ltd. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names League Jinn Sarl (filed 2026-05-04).
Who are NLS Pharmaceutics Ltd.'s owners and officers?
NLS Pharmaceutics Ltd.: industry Pharmaceutical Preparations (Form D, 2026-08-24).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-08-24)
- : Executive Officer, Director (Form D, 2026-08-24)
- : Executive Officer (Form D, 2026-08-24)
- : Executive Officer (Form D, 2026-08-24)
- : Executive Officer, Director (Form D, 2026-08-24)
- : Director (Form D, 2026-08-24)
- : Director (Form D, 2026-08-24)
- : Director (Form D, 2026-08-24)
- : Director (Form D, 2026-08-24)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D, 2026-05-04 | League Jinn Sarl | 25.3% |
| Schedule 13D, 2025-11-14 | Michel Revel | 20.2% |
| Schedule 13G, 2025-11-13 | League Jinn Sarl | 21.6% |
| Schedule 13D, 2025-11-13 | Ronen Twito | 6% |
| Schedule 13G, 2025-11-07 | Clover Wolf Capital - Limited Partnership | 7.5% |
| Schedule 13G/A, 2025-11-04 | Bvf Gp Holdings LLC | 0.6% |
Questions about who owns NLS Pharmaceutics Ltd.
Who owns NLS Pharmaceutics Ltd.?
On this page, 4 holders' latest ownership filings report 5% or more of NLS Pharmaceutics Ltd.: League Jinn Sarl (25.3%, Schedule 13D, filed 2026-05-04), Michel Revel (20.2%, Schedule 13D, filed 2025-11-14), Clover Wolf Capital - Limited Partnership (7.5%, Schedule 13G, filed 2025-11-07) and Ronen Twito (6%, Schedule 13D, filed 2025-11-13).
Who are the largest shareholders of NLS Pharmaceutics Ltd.?
By the share each holder's latest filing reports, the largest holders of NLS Pharmaceutics Ltd. on this page are League Jinn Sarl (25.3%), Michel Revel (20.2%) and Clover Wolf Capital - Limited Partnership (7.5%).
When did League Jinn Sarl buy into NLS Pharmaceutics Ltd.?
The filings give report dates, not purchase dates. The earliest filing from League Jinn Sarl on this page is the Schedule 13G, filed 2025-11-13, reporting 21.6%; its latest, Schedule 13D filed 2026-05-04, reports 25.3%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on NLS Pharmaceutics Ltd.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on NLS Pharmaceutics Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NLS Pharmaceutics Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own NLS Pharmaceutics Ltd. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the cso and a director: 957,530 shares (20.0% of shares outstanding) (Form 4, 2026-04-29).
- , the chairman and chief executive: 272,399 shares (5.7% of shares outstanding) (Form 3, 2026-03-18).
- , a director: 81,818 shares (1.7% of shares outstanding) (Form 4, 2026-04-29).
Shares outstanding: 4,797,505 as of 2025-12-31, from the company's latest SEC cover page.
How much has NLS Pharmaceutics Ltd. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-08-24 | $2.94M | $2.94M |
| Form D, 2026-05-13 | $3.43M | $3.43M |
| Form D, 2025-07-10 | $1M | $1M |
| Form D, 2025-04-14 | $2M | $2M |
| Form D, 2025-01-22 | $500K | $500K |
| Form D, 2024-10-21 | $7.20M | $7.20M |
| Form D, 2024-07-15 | $787K | $787K |
| Form D, 2024-04-03 | $1.75M | $1.75M |
Latest IPO step: NLS Pharmaceutics Ltd. filed to go public (F-1, 2025-09-25).
IPO filings: F-1, 2025-09-25, F-1, 2024-08-27; ticker NLSP on Nasdaq Capital Market.
Keep reading
More on NLS Pharmaceutics Ltd. and the records around it.
NLS Pharmaceutics Ltd. elsewhere on the record
- Company profile and every filing Aug 2026
- Form D filing Aug 2026
- Form D filing May 2026
- 5%+ stake filings May 2026
Companies that share a holder
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Related pages
Funding and filing history5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/newcelx-ltd